Bristol-Myers Squibb Co. (BMY) News

Bristol-Myers Squibb Co. (BMY): $74.45

1.68 (+2.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter BMY News Items

BMY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BMY News Highlights

  • BMY's 30 day story count now stands at 35.
  • Over the past 27 days, the trend for BMY's stories per day has been choppy and unclear. It has oscillated between 1 and 22.
  • The most mentioned tickers in articles about BMY are DRUG, AMP and BEAT.

Latest BMY News From Around the Web

Below are the latest news stories about BRISTOL MYERS SQUIBB CO that investors may wish to consider to help them evaluate BMY as an investment opportunity.

Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?

Shares in pharmaceutical company Bristol Myers Squibb (NYSE: BMY) are up a little more than 11% over the past year. The company posted third-quarter revenue of $11.2 billion, a decrease of 3%, with one culprit being the loss of exclusivity for one of its blockbuster drugs, Revlimid. The blood cancer therapy reported sales of $2.4 billion, down 28% year over year.

Yahoo | February 4, 2023

Bristol-Myers Squibb Full Year 2022 Earnings: In Line With Expectations

Bristol-Myers Squibb ( NYSE:BMY ) Full Year 2022 Results Key Financial Results Revenue: US$46.2b (flat on FY 2021). Net...

Yahoo | February 4, 2023

Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference

Business Wire | February 3, 2023

Company News for Feb 3, 2023

Companies in The news Are: META, BMY, PH, CAH.

Yahoo | February 3, 2023

Bristol-Myers Squibb Company (BMY) Q4 2022 Earnings Call Transcript

Bristol-Myers Squibb Company (BMY)

Q4 2022 Earnings Conference Call

February 2, 2023 9:00 AM ET

Company Participants

Timothy Power - VP & Head, IR

Giovanni Caforio - Chairman & CEO

David Elkins - EVP & CFO

Christopher Boerner - EVP & Chief Commercialization Officer

Samit Hirawat - EVP & Chief Medical Officer, Global Drug Development

Conference Call Participants

Geoffrey Meacham - Bank of America

Chris Shibutani - Goldman Sachs

Christopher Schott - JPMorgan

Seamus Fernandez - Guggenheim Securities

Stephen Scala - Cowen and Company

Timothy Anderson - Wolfe Research

Evan Seigerman - BMO Capital Markets

Terence Flynn - Morgan Sta...

SA Transcripts on Seeking Alpha | February 2, 2023

The Big Pharma axe: Merck cuts chikungunya vax, Bristol Myers drops CytomX-partnered programs, and more

As fourth quarter earnings come in, Big Pharmas are disclosing changes to their pipelines during their investor calls, and sometimes more quietly in presentation appendices. Merck dropped its chikungunya vaccine candidate, which completed a Phase II study. Merck acquired the vaccine through its purchase of Themis Bioscience in 2020. In

Endpoints News | February 2, 2023

Bristol Myers'' profit beats on better-than-feared Revlimid sales

Bristol Myers Squibb Co on Thursday reported quarterly earnings that beat analysts'' estimates due to a smaller-than-expected drop in sales of cancer drug Revlimid, which is facing competition from cheaper generic rivals.

Reuters | February 2, 2023

Here''s How to Trade Bristol-Myers Squibb After Earnings

If you''re a long-term BMY bull, here''s what the charts suggest….BMY

The Street RealMoney | February 2, 2023

Revlimid Generic Competition Hurts Bristol Myers'' Q4 Earnings, Issues Annual Outlook Within Expected Range

Bristol Myers Squibb & Co (NYSE: BMY ) said that its Q4 sales of $11.41 billion fell 5% Y/Y as generic competition impacted sales of its blockbuster cancer drug Revlimid in the U.S. and foreign exchange impacts, partially offset by in-line products (primarily Opdivo) and new product portfolio (primarily Opdualag and Abecma). Analysts estimated Q4 sales of $11.20 billion. Sales of Revlimid fell 32% to … Full story available on Benzinga.com

Benzinga | February 2, 2023

Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World

Pharmaceutical majors Merck & Co (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), and Eli Lilly & Co (NYSE:LLY) have reported fourth-quarter numbers at…

TipRanks | February 2, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5432 seconds.